MedTrace Logo

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

NCT06914037 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-04-06

No results posted yet for this study

Summary

Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies

Conditions

  • Peripheral T-cell Lymphoma
  • Cutaneous T-cell Lymphoma (CTCL)
  • NHL (Non-Hodgkin Lymphoma)

Interventions

DRUG

CHT101

CD70 UCAR-T

Sponsors & Collaborators

  • Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.

    collaborator INDUSTRY

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06914037 on ClinicalTrials.gov